Similar to previous reports in which the number of serum EVs was increased in human patients with various tumors [22,23], the number of sera ALIX+ EVs was increased in tumor-bearing mice compared to control mice (Fig. 2E), see supernatant panel and control αRbt IgG bead treatment. This evidence concerns the gene PDCD6IP and neoplasm.